OBIO logo

ORCHESTRA BIOMED HOLDINGS IN

OBIONASDAQ
🏆 #3245 by market capEarnings Nov 9US Equity
$6.09▲ $0.22 (+3.66%)
Market closed · at close
🔔
Track OBIO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$364M
Small Cap
📈Revenue Growth (YoY)
+1169.2%
High Growth
📊Gross Margin
99.3%
High
💵FCF Margin
-184.8%
Thin
⚖️P/S Ratio
11.0x
Elevated
Otter Score
68
Fair
No chart data available for OBIO.

Trading Snapshot

Day Range
$6.02 – $6.12
52-Week Range
$2.40 – $6.48
Volume
$2.70B
Avg Volume
$2.00B
Shares Outstanding
59.9M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$33M
Last Q Revenue
$88,000
P/E Ratio
-5.9
P/S Ratio
11.0x
EPS (TTM)
$-0.93
Dividend Yield
0.00%
Dilution (1yr)
+31.3%

Why Investors Own OBIO

  • ✓High-growth profile — revenue up +6.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 70% gross margin and 11% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OBIO logo

ORCHESTRA BIOMED HOLDINGS IN

OBIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$33M▲ +1169.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.4%▲ +7.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$52M▼ −19.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$49M▼ −2.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
50.0M▲ +31.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$3M YoY
StockOtter · stockotter.space

About ORCHESTRA BIOMED HOLDINGS IN

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$6.98
▲ +14.7% Upside
High Target$8.70
Low Target$6.09
Based on 19 analysts

Latest News & Updates

🚀
CNBC·2h ago

ORCHESTRA BIOMED HOLDINGS IN tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift OBIO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

ORCHESTRA BIOMED HOLDINGS IN announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.